[{"address1": "Maxim 1", "address2": "2 Parklands Way Holytown", "city": "Motherwell", "zip": "ML1 4WR", "country": "United Kingdom", "phone": "44 14 1433 7557", "website": "https://tcbiopharm.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.", "fullTimeEmployees": 41, "companyOfficers": [{"maxAge": 1, "name": "Mr. Bryan L. Kobel", "age": 44, "title": "CEO & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 544560, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Martin E. Thorp", "age": 71, "title": "CFO & Director", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 410521, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Camarra", "title": "Executive Vice President of Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lauren  Bor Ph.D.", "title": "Head of Commercial Development Division", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.17, "open": 1.05, "dayLow": 1.02, "dayHigh": 1.09, "regularMarketPreviousClose": 1.17, "regularMarketOpen": 1.05, "regularMarketDayLow": 1.02, "regularMarketDayHigh": 1.09, "forwardPE": -0.23478262, "volume": 260898, "regularMarketVolume": 260898, "averageVolume": 4815965, "averageVolume10days": 204170, "averageDailyVolume10Day": 204170, "bid": 1.07, "ask": 1.1, "bidSize": 200, "askSize": 100, "marketCap": 5340740, "fiftyTwoWeekLow": 0.85, "fiftyTwoWeekHigh": 196.0, "fiftyDayAverage": 1.34308, "twoHundredDayAverage": 26.987526, "currency": "USD", "enterpriseValue": 107562024, "floatShares": 98778023, "sharesOutstanding": 4945130, "sharesShort": 131198, "sharesShortPriorMonth": 237548, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.026500002, "heldPercentInsiders": 0.00022, "heldPercentInstitutions": 0.00664, "shortRatio": 0.06, "shortPercentOfFloat": 0.0294, "impliedSharesOutstanding": 3195130, "bookValue": 1.051, "priceToBook": 1.0275928, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -8593896, "trailingEps": -19.44, "forwardEps": -4.6, "lastSplitFactor": "1:20", "lastSplitDate": 1702598400, "enterpriseToEbitda": -8.323, "52WeekChange": -0.9918182, "SandP52WeekChange": 0.23232913, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TCBP", "underlyingSymbol": "TCBP", "shortName": "TC BioPharm (Holdings) plc", "longName": "TC Biopharm (Holdings) Plc", "firstTradeDateEpochUtc": 1644589800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ef544858-646b-3e8d-bcb0-2aed3539a593", "messageBoardId": "finmb_1681274131", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.08, "targetHighPrice": 140.0, "targetLowPrice": 140.0, "targetMeanPrice": 140.0, "targetMedianPrice": 140.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 980955, "totalCashPerShare": 0.01, "ebitda": -12923699, "totalDebt": 1728127, "quickRatio": 0.448, "currentRatio": 0.882, "debtToEquity": 159.939, "returnOnAssets": -1.08915, "returnOnEquity": -5.56679, "freeCashflow": -6853025, "operatingCashflow": -10042216, "financialCurrency": "GBP", "trailingPegRatio": null, "__fetch_time": "2024-06-10"}]